Immediate Impact
2 from Science/Nature 63 standout
Citing Papers
Epigenetics-targeted drugs: current paradigms and future challenges
2024 Standout
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
2023 Standout
Works of Dai Maruyama being referenced
Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma
2021
Phase I / II study of brentuximab vedotin in J apanese patients with relapsed or refractory CD 30‐positive H odgkin's lymphoma or systemic anaplastic large‐cell lymphoma
2014
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Dai Maruyama | 970 | 788 | 310 | 162 | 1.5k | |
| Joo Y. Song | 905 | 907 | 317 | 129 | 1.7k | |
| Girish Venkataraman | 1016 | 983 | 423 | 83 | 1.9k | |
| Emmanuel Bachy | 1134 | 1230 | 422 | 182 | 2.1k | |
| Stephen D. Smith | 939 | 719 | 557 | 123 | 1.6k | |
| Daisuke Ennishi | 920 | 639 | 428 | 107 | 1.5k | |
| Hirokazu Nakamine | 907 | 706 | 310 | 100 | 1.5k | |
| Carla Casulo | 1227 | 1030 | 527 | 94 | 1.8k | |
| Giulio Fraternali Orcioni | 896 | 633 | 334 | 79 | 1.8k | |
| Dai Chihara | 1147 | 889 | 640 | 123 | 2.1k | |
| Alessandro Broccoli | 1204 | 613 | 315 | 113 | 1.6k |
All Works
Login with ORCID to disown or claim papers
Loading papers...